Novartis reveals impressive four year data upon Cosentyx
pharmafile | October 3, 2016 | News story | Sales and Marketing |Â Â Cosentyx, Novartis, psoriasisÂ
Novartis announced on October 1 that Cosentyx (secukinumab) had delivered a high percentage and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis over the course of a four year treatment. This includes in previously difficult to treat areas, which are the hands and the feet.
Psoriasis is a chronic immune-mediated disease characterized by thick and extensive skin lesions (plaques), which can cause itching, scaling, and pain. The goal of psoriasis treatment is clear skin, and the Psoriasis Area Severity Index (PASI) 90 response is considered an important measure of treatment success. Clear or almost clear skin (PASI 90) was achieved by 68.5% of patients at Year 1 and this rate was maintained to Year 4 (66.4%). In addition, 43.8% of psoriasis patients achieved completely clear skin (PASI 100) at Year 1 and this rate (43.5%) was maintained to Year 4. The average improvement of psoriasis, measured by the PASI score, was maintained at over 90% after 4 years of treatment. The standard goal of treatment, PASI 75 response, was achieved by 88.5% of patients at Year 4.
“These impressive results show that Cosentyx keeps working year-on-year, maintaining high levels of skin clearance with a favorable safety profile,” said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, at Novartis. “Psoriasis patients need therapies they can use over long periods of time without loss of efficacy and we are pleased that Cosentyx is proving a sustainable choice for patients.”
Ben Hargreaves
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …
